Ireland· IE-PA-EU/1/20/1442/002-003
Zeposia 0.92 mg hard capsules
A ozanimod product containing ozanimod, registered in Ireland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 2 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Ozanimod is registered in 2 of 19 countries.
Countries holding a registration under ATC L04AA38 (ozanimod), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 1 of them publish a price we can compare per daily dose
Ozanimod · ATC L04AA38
2 / 19 countries
- Ireland
- Polandprice
The record
At a glance
HPRA (Ireland)- Active substance
- OZANIMOD
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Ireland (IE)
- ATC code
- L04AA38
- ATC class
- Ozanimod
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/20/1442/002-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
852 interactions on record for ozanimod.
Graded by severity as the source publishes them — 578 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ozanimod · interactions on record
852 records
- 578 severe
- 271 moderate
- 3 minor
Most severe, free to view
- FamotidineA02BA03severe
- PapaverineA03AD01severe
- IsomethepteneA03AX10severe
- CisaprideA03FA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ozanimod in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZEPOSIABristol-Myers Squibb Pharma EEIG, Dublin
- CanadaZEPOSIABRISTOL-MYERS SQUIBB CANADA
- SwitzerlandZeposia 0.92 mg, HartkapselnBristol-Myers Squibb SA
- SpainZEPOSIA 0,92 MG CAPSULAS DURASBristol-Myers Squibb Pharma Eeig
- FinlandZeposiaBristol-Myers Squibb Pharma EEIG
- United KingdomZeposia 0.92mg capsulesBristol-Myers Squibb Pharmaceuticals Ltd
- IcelandZeposiaBristol-Myers Squibb Pharma EEIG*
- NetherlandsZeposia 0,92 mg capsule, hardBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zeposia
- Liechtenstein · Zeposia
- Norway · Zeposia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8ec736f6-bc0d-4dc1-aa42-3c42846fcd9e GET /v1/drugs/8ec736f6-bc0d-4dc1-aa42-3c42846fcd9e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L04AA",
"L04AA38"
],
"strength": null,
"pa_number": "EU/1/20/1442/002-003",
"substances": [
"OZANIMOD"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "20/05/2020",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ozanimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.